(NASDAQ:BIIB) LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease
after initial treatment of 18 months
Related Questions
How will the FDA approval of LEQEMBI® IQLIK™ affect Biogen's (BIIB) stock price in the short and medium term?
What is the expected market share and revenue potential of the at‑home subcutaneous formulation compared with existing anti‑amyloid therapies and competitors?
What are the reimbursement, pricing and payer acceptance outlook and potential risks for commercial uptake of the new maintenance dosing regimen?